Post-earnings recap
Reported
Tue, May 6, 2025
EPS actual
$-0.78
EPS est.
$-0.71
EPS surprise
-9.09%
1-day move
-12.63%
Est. EPS
—
Est. Rev
—
Impl. Move
—
Denali Therapeutics reported a larger-than-expected loss per share, which contributed to a significant drop in stock price. The lack of revenue data and guidance updates may have added to investor concerns. The stock's 12.63% decline reflects market disappointment with the earnings performance and uncertainty about future prospects.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.78 | N/A | -9.09% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a cautious outlook, highlighting ongoing challenges. They reiterated their commitment to long-term strategies.
Management acknowledged the challenges faced this quarter.
They emphasized a focus on long-term goals despite short-term setbacks.